Biodexa Pharmaceticals (NASDAQ: BDRX) — Perfil da empresa, notícias e dados financeiros
Biodexa Pharmaceuticals focuses on innovative drug therapies for oncology and infectious diseases, advancing medical science.
Biodexa Pharmaceticals
Biodexa Pharmaceuticals (NASDAQ:BDRX) specializes in developing innovative drug therapies aimed at treating a wide range of diseases, with a strong emphasis on oncology, neurological disorders, and infectious diseases. The company's robust pipeline includes both early-stage experimental drugs and those in later stages of clinical trials, demonstrating a commitment to advancing medical science and improving patient outcomes. Biodexa Pharmaceuticals is dedicated to leveraging cutting-edge technology and research to hasten the delivery of new, effective treatments to the market. By focusing on unmet medical needs, the company aims to significantly impact global health outcomes. Biodexa Pharmaceuticals' projects span across various critical segments of healthcare, reflecting its objective to emerge as a pioneer in delivering transformative therapeutic solutions.
Resumo
Operações
Produtos e/ou serviços de Biodexa Pharmaceticals
- Development of an advanced oncology drug targeting non-small cell lung cancer, enhancing patient survival rates and quality of life.
- Research and formulation of a novel antibiotic effective against multi-drug resistant bacteria, addressing the growing global antibiotic resistance crisis.
- Production of high-quality, affordable insulin for diabetes patients, focusing on accessibility and reliability to manage this chronic condition efficiently.
- Introduction of a new, innovative Alzheimer's treatment, aimed at slowing disease progression through targeting brain plaque accumulation.
- Launch of a comprehensive cardiovascular health program, including medications and lifestyle guidance to prevent heart disease and improve patient outcomes.
- Creation of a mobile application for personalized medication management, integrating reminders, health tracking, and pharmacist consultations to improve adherence and patient experience.
equipe executiva do Biodexa Pharmaceticals
- Stephen Anthony StampCEO & Director
- Fiona Mary SharpCompany Secretary, CFO & Director
- Daniel PalmerChief Science Officer
- Steve EllulChief Business Officer
- Gary A. ShangoldChief Medical Officer
- Jim KostkaVice President & Head of US Clinical Operations
- Noreen BhattiVice President of Clinical Operations
Últimas notícias sobre a Biodexa Pharmaceticals
Principais indicadores financeiros
Resultados divulgados pela Biodexa Pharmaceticals, em GBP.
- Cap. de mercado
- 1,1 mi
- Receita (TTM)
- 83 mil
- P/L
- 0.0
- LPA (diluído, TTM)
- 530.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -8,3 mi | -6,2 mi | |
| 0 | -9,2 mi | -5,7 mi | |
| 381 mil | -8 mi | -7,1 mi | |
| 699 mil | -8,9 mi | -7,7 mi |